http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108434459-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate | 2018-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108434459-B |
| titleOfInvention | Polypeptide drug conjugate and preparation method and application thereof |
| abstract | The invention provides a polypeptide drug conjugate and a preparation method and application thereof, wherein the polypeptide drug conjugate comprises ticagrelor and CREKA polypeptide, and the ticagrelor is connected with the CREKA polypeptide; compared with the existing platelet inhibitor, the polypeptide drug conjugate provided by the invention has the advantages that the ticagrelor is connected with the polypeptide, so that the high-concentration enrichment of tumor tissue parts can be realized, the high-concentration enrichment of atherosclerotic tissues can also be realized, the function of inhibiting platelets in a specific area can be realized without influencing the platelet function in the normal blood circulation process, the drug availability is increased, the bleeding risk of the conventional platelet inhibitor is reduced, and the function of better and safer tumor metastasis inhibition or acute coronary syndrome prevention is realized. |
| priorityDate | 2018-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.